The use of monodonal antibodies (mAbs) directed to lipid A for the therapy of gram-negative sepsis is controversial. In an attempt to understand their biologic basis of action, we used a fluidphase radioimmunoassay to measure binding between bacterial lipopolysaccharide (LPS) and two IgM mAbs directed to lipid A that are being evaluated for the treatment of gram-negative bacterial sepsis. Both antibodies bound 3H-LPS prepared from multiple strains of gram-negative bacteria when large excesses of antibody were used, although binding was modest and only slightly greater than control preparations. We also studied the ability of each anti-lipid A antibody to neutralize some of the biological effects of LPS in vitro. Despite large molar excesses, neither antibody neutralized LPS as assessed by the limulus lysate test, by a mitogenic assay for murine splenocytes, or by the production of cytokines interleukin (IL)-I, II.-6, or tumor necrosis factor from human monocytes in culture medium or in whole blood. Our experiments do not support the hypothesis that either of these anti-lipid A mAbs function by neutralizing the toxic effects of LPS.
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I
n 1968, Chedid et al. (1) reported that the passive infusion of antiserum raised to killed rough mutant bacteria protected mice against challenge with heterologous gram-negative bacteria. Rough mutant bacteria are unable to incorporate O-polysaccharide onto the glycolipid of LPS, and therefore expose the deeper core structures of endotoxin on their surface. These authors proposed that a few antibodies or serum factors specific for the endotoxin core could "have the capability of coping, like masterkeys, with a very wide range of infections due to serologically unrelated organisms" (1) . Over the next two decades, several laboratories studied the ability of antisera raised to two bacterial mutants, Escherichia coli J5 and Salmonella minnesota Re595, to protect in animal models of endotoxic shock. Most (1-7), but not all (8, 9) , of these studies confirmed that passively transferred antisera raised to these organisms protect against challenge with heterologous LPS in animal models. A clinical trial indicated that polyclonal antiserum raised to E. coli J5 was therapeutic for patients with gram-negative sepsis (10) . Two lines of evidence suggested that the protective element in these antisera was Ig directed against common epitope(s). First, purified Ig fractions prepared from the polyclonal antisera protected in animal models (4, 11, 12) . Second, the protective activity in the antisera could be adsorbed with the rough mutant LPS or bacteria, but not with control heterologous LPS or bacteria (1, 5, 6, 13, 14) . The concept evolved that some of the Ig in these antisera cross-reacted with LPS from multiple gramnegative strains, and therefore was able to "cross-protect" against heterologous strains. Cross-reactive Ig was hypothesized to protect by neutralizing the toxic effects of endotoxin (10) .
Several investigators have generated mAbs to structures on the core glycolipid of LPS (15) (16) (17) (18) (19) (20) . Two of these, HA-1A (Centocor, Malvern, PA) and E5 (XOMA, Berkeley, CA), have been studied in human trials which enrolled patients with suspected gram-negative sepsis (16, 21, 22) . HA-1A is a human IgM mAb that binds to lipid A (15) . This antibody has been reported to protect in some animal models (15, 23) , although in other models, the protection has been only modest (24, 25) . The protective efficacy of HA-1A for gramnegative sepsis has been studied in a single double-blind, randomized, placebo-controlled clinical trial (21) . In this study, administration of HA-1A was associated with decreased 28-d all-cause mortality in a subgroup of patients that had gramnegative bacteremia. HA-1A is licensed for use as a therapy for gram-negative sepsis in some countries in Europe. E5 is a murine IgM mAb which also binds to lipid A (16) . There are few data available regarding the ability of E5 to protect in animal models. Two articles suggest that it provides slight protection against endotoxin (26) or bacterial challenge (27) . E5 has been evaluated in two clinical trials. In the first trial, administration of E5 was associated with increased survival in a subset of patients with gram-negative sepsis who were not in refractory shock (16) . In the second trial, there was apparently no improved survival in patients with documented gram-negative sepsis, although these results have been presented in abstract form only (22) .
Because a proposed mechanism of action of these two antibodies is to bind and neutralize LPS, we studied the ability of each to bind the LPS from multiple clinical strains of gramnegative bacteria. The results of solid-phase immunoassays can be difficult to interpret because of nonspecific interactions and the amphipathic nature of LPS. Accordingly, we used a fluid-phase RIA to measure antibody-LPS binding. We also evaluated the ability of each anti-lipid A antibody to neutralize the effects of LPS in several in vitro assays of endotoxin bioactivity. We found that both HA-1A and E5 bound slightly to LPS from multiple smooth strains of gramnegative bacteria when large excesses of antibody were used. However, neither antibody neutralized LPS as assessed by the limulus lysate test, by a mitogenic assay for murine splenocytes, or by the production of the cytokines IL-1, Ib6, or TNF from human monocytes in culture medium or in whole blood. Our experiments do not support the hypothesis that either of these two anti-lipid A mAbs function by binding and neutralizing the toxic effects of LPS. Biosynthetically radiolabeled strains orE. coli strains (except for E. coliJS) were prepared by growing the organisms in the presence of [3H]acetate followed by hot phenol extraction as previously described (29) . Briefly, we grew cultures of each organism to an OD of 0.9 at 540 nm (with a path length of 1.0 cm) in broth containing, per liter, 22.5 g of yeast extract, 11 g peptone, 4 g of monobasic potassium phosphate, 16.8 g of diabasic potassium phosphate, and 10 g of glucose, in the presence of 10 mCi of [3H]acetate per 100 ml broth. The cells were chilled and washed three times in saline, and the LPS was extracted by the hot phenol method (30 Radiolabded LPS from E. coli J5 was made by growing the organisms in broth containing [3H]acetate as described above, and extracting the LPS as described by Galanos et al. (33) . This LPS contained 22,000 cpm/#g.
Materials and Methods

LPS
Antibodies and Controls
The human anti-lipid A IgM mAb (HA-IA, Centoxin) used in the study was from Centocor B.V. (Leiden, The Netherlands). It was supplied as a 5 mg/ml solution containing 5% human serum albumin. Murine anti-lipid A IgM mAb (E5) was the kind gift of Dr. Robert Kubin (Infectious Disease Unit, Massachusetts General Hospital). It was supplied as a 2 mg/ml solution in PBS, pH 7. 
Fluid-phase RIA
Radiohbeled LPS was incubated in dilutions of each mAb or controls at 37~ Complexes of [3H]LPS bound to protein were then separated from free [3H]LPS by precipitation in half-saturated ammonium sulfate according to the method of Farr (34) .
Specifically, 5/zg/ml of each smooth LPS tested was incubated in 150/A of dilutions of the mAb to be tested in .01 M PBS, pH 7.3 for 120 n'fin at 37~ in a 1.5-ml microcentrifuge tube. Controis were human serum albumin (HSA), polyclonal human IgM, human myeloma IgM, polydonal murine IgM, and a marine IgG mAb directed to the O-polysaccharide of E. coli Ol11:B4. After incubation, the solution was cooled on ice for 15 min. An equal volume of iced saturated ammonium sulfate was then added dropwise and the solution was allowed to sit at 4~ for another 15 min. The tubes were next centrifuged at 12,000 g for 15 min. Supernatants were carefully aspirated, and pellets were washed twice with 50% ammonium sulfate and resuspended in 300/zl of PBS.
1 Abbreviations used in this paper: HSA, human serum albumin; LAL, limuhs amoebocyte lysate.
The quantities of LPS in the supernatants and pellets were assessed by counting 0.4 ml of a 1:7 dilution of each combined with 4.5 ml ofoptiflor scintillation fluid (Packard Instrument Co.). Quenching was minimal and was corrected by using the internal standard method. Greater than 99% of the HA-1A was documented to be in the pellet after precipitation with 50% ammonium sulfate as assessed by a capture IgM ELISA technique. Greater than 80% of E5 was found in the pellet after precipitation as assessed by a protein assay using bicinchoninic acid (Pierce Chemical Co., Rockford, IL). Less than 5% of each smooth LPS tested precipitated in PBS alone. However, >90% of the [3H]LPS from rough mutant E. coliJ5 precipitated in PBS-HSA alone, so that we were unable to test this LPS in the system. For most oftbe assays, recovery of radioactivity was >85% using this assay. At low protein concentrations (<50/~g/ml), recovery was sometimes less, which we attributed to LPS binding to the walls of the tube. All assays were performed in duplicate and the results are given as means. Results were calculated as percent recovered cpm as determined by the formula: 100• (cpm in the pelht/cpm recovered), expressed to the nearest whole percentage point. Results are given as the mean of at least two experiments.
LAL Assay
A spectmphotometric LAL assay was used as previously described (35) . Briefly, 50/~1 of a solution of 20/zg/ml of each mAb in pyrogen-free saline were incubated with 50 #1 of dilutions of LPS for 30 rain at 37~ in a 96-well microtiter plate. 100/zl of LAL were then added, and the plate was incubated at 37~ for an additional 60 rain. Coagulation of the LAL was measured spectrophotometrically at OD~ in an automated ELISA reader. Coagnlation of the LAL in the presence of HA-1A or E5 was compared with coagulation of the LAL in saline alone.
Mitogenic Assay
The mitogenic assay was performed essentially as described by Jacobs et al. (36) . Briefly, dilutions of LPS were preincubated in the presence of 625/~g/ml mAb or control, or 50/~g/ml polymyxin B for 2 h at 37~ This solution was then diluted in RPMI media supplemented with antibiotics containing 0.01 M Hepes and 10% FCS and incubated in a volume of 200/~1 for 48 h with 5 x 106 spleen cells from BALB/c mice. The final antibody or HSA control concentrations in culture were 25/~g/well and the final polymyxin B concentration in culture was 2/zg/weU. 1 IzCi of [~H]thymidine was next added to each well, and cells were incubated for an additional 16 h. Incorporated radioactivity was measured using a cell harvester (Cambridge Technology, Inc., Watertown, MA) to disrupt the cells followed by scintillation counting. Each assay was done in quadruplicate, and the results are given as the mean.
Cytokine Assays
Preparation and Treatment of Human Monocytes. PBMC were obtained by centrifugation on Ficoll (MSL; Eurobio, Les Ulis, France) of 1:2 diluted heparinized venous blood from healthy adult volunteers. Monocytes were selected by allowing the mononuclear ceUs to adhere to plastic culture dishes (24 wells; Nunc, Roskilde, Denmark) in the absence of serum (37) . More than 85% of the adherent cells were monocytes, as assessed by morphological analysis by phase-contrast microscopy, histochemical staining for nonspecific esterase activity (38) , and indirect immunofluorescence staining using antilymphocyte antibodies, OKTll (Ortho Diagnostics, Inc., Raritan, NJ) and IOBI (Immunotech, Marseille, France). Human mononuclear adherent cells (5 x 10 s nonspecific esterase-positive cells per well), cultured in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 100 IU of penicillin per ml and 100/~g of streptomycin per ml, were incubated for 24 h in the presence of free LPS, or in the presence of LPS that had been incubated previously with dilutions of anti-lipid A antibodies or 2/~g/ml polymyxin B for I h at 37~ in culture medium containing 3.3% decomplemented normal human serum. These solutions were then added to the cells so that the final serum concentration in all cultures was 0.2%. Final reaction mixtures contained the indicated amounts of antibody and LPS in a volume of 0.5 ml per well. Culture supernatants were collected and centrifuged at 3,000 g for 15 min and assayed for cytokines. II.,1 found in the supernatant will be referred to as IL-1 or released IL-1. The adherent cells were then lysed by three freeze-thaw cycles in 0.5 ml of fresh RPMI 1640 medium, and the lysates were centrifuged at 3,000 g for 15 min. The II.,1 found in these supernatants will be referred to as cell-associated IL-1,
Whole Blood Cytokine Assays. The induction of cytokines by LPS in whole blood was measured as described (39) . Briefly, 500 /~1 blood diluted 1:5 in RPMI-1640 culture medium per well was cultured in the presence of free LPS, or LPS that had been preincubated with antibodies or polymyxin B. Preincubations (LPS alone or with antibodies or polymyxin B) were performed in the presence of 3.3% decomplemented normal human serum as described above. Final reaction mixtures contained the indicated amounts of antibody and LPS, Cytokines were assayed after 24 h of culture.
TNF Assay. An ILIA specific for TNF-ot was performed according to Munoz et al. (37) with minor modifications. Briefly, on day 1, 100 #1 of a rabbit anti-TNF-c~ antiserum (a kind gift of Catherine Rougeot, Institut Pasteur) diluted ~:8,200 to precipitate 35% of the radiolabded TNF was added to 100/zlof standards or samples. To determine the nonspecific binding, 100/~1 of BSA buffer was added to a tube instead of sample. Then 300/zl of BSA buffer was added to each tube. After vortexing, the tubes were incubated for 24 h at room temperature. Standards of TNF-a (Rhone Poulenc, Vitry-sur-Seine, France) containing 0, 40, 80, 150, 300, 600, 1,250, 2,500, 5,000, and 10,000 pg/ml were employed. On day 2, 100/~1 of a solution of uSI-TNF-ol (30/zCi/#g, New England Nuclear, Boston, MA) containing =10,000 cpm was added to each tube. The tubes were vortexed and incubated at room temperature for 24 h. On day 3, 500/~1 of BSA buffer containing 6% of polyethylene glycol 8000 (Sigma Chemical Co.), 1% of horse anti-rabbit IgG, and 0.1% of normal rabbit serum were added. The tubes were vortexed and incubated for 2 h at 4~ The tubes were then centrifuged at 1,500 g for 15 min at room temperature. Thereafter, the supernatants were discarded and the tubes were kept inverted for 30 min and drained on absorbent paper. Tubes were counted in a gamma counter, and the value for nonspecific binding was subtracted. All standards and samples were expressed as percent standard containing no TNF-o~ (zero standard). The concentrations of TNF-ot in pg/ml on a logarithmic x-axis were plotted against the binding percentage on a logarithmic y-axis. The standard curve obtained was used to determine the concentrations of TNF-c~ in samples. The detection limit was 70 pg/ml.
11,I Assay.
A similar ILIA protocol as that used for TNF-c~ measurement was employed to determine concentrations of ID1B. Standard IL-1B was obtained from Rhone Poulen~ Rabbit anti-IZ-13 antisermn (1:150) was purchased from Endogen, Inc. (Boston, MA), and 12sI-IL-1B (126-253 (/zCi//zg) was obtained from New England Nuclear. On day 3, 500 #1 of BSA buffer containing 6% polyethylene glycol 8000, 1% of sheep anti-rabbit IgG (Sigma Chemical Co.), and 0.05% normal rabbit serum were added to each tube. Determination of IL-1B concentrations in plasma and samples were calculated as described above. The detection limit was 70 pg/ml. The IL-lct concentrations were determined by ELISA using two anti-IL-lt~ mAbs as described (37) . Briefly, on day 1, ELISA microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) were coated with 100/zl of monoclonal mouse IgG1 anti-rhlblot (10/~g/ml in carbonate buffer) and incubated 2 h at 37~ The plates were washed three times with 0.1% Tween 20 PBS. Standards (0, 10, 30, 300, 1,000, 3,000, and 10,000 pg(ml rhlblt~) or cell supernatant or cell lysate samples diluted in 1% BSA, 0.1% Tween 20 PBS were added to coated wells and incubated overnight at 4~ On day 2, the plates were washed three times and 100/zl of the second monoclonal mouse anti-rhlI~lc~ (IgG2b) (1:2,000 in BSA/Tween/PBS) were added into each well. Plates were incubated for 3 h at 37~ After washing, 100 #1 of peroxidase-conjugated anti-mouse lgG2b (1:5,000) (Southern Biotechnology Associates, Inc., Birmingham, AL) were added to each well and the plates were left for 1 h at 37~ After washing, enzymatic activity was detected with a phosphate citrate buffer containing 1 mg/ml O-phenylenediamine dihydroxychloride (Sigma Chemical Co.) and hydrogen peroxide (0.06%). The reaction was stopped with 50/zl of3N HC1, and the absorbance was read at 492 nm on a microplate reader (Titertek multiskan MC340; Flow Laboratories, Inc., McLean, VA). The levels of II-lct in the samples were calculated by reference to the standard curve. The detection limit of Iblot was 30 pg/ml.
11.,6
Bioassay. IL-6 activity was determined as described (37) by using the specific 7TD1 IL-6-dependent cell line (40) kindly provided by D~ J. Van Snick (Ludwig Institute for Cancer Research, Brussells, Belgium). Cells were cultured at a density of 1,200 cells/well (96-well multidish plates; Falcon Labware, Oxnard, CA) in 100/zl of RPMI medium supplemented with antibiotics, 2-ME (5 x 10 -s M) and 10% FCS, in the presence of serial dilutions of cell supernatants, After 4 d of culture at 37~ the proliferation was monitored by a dye method. Briefly, 125/zg of tetrazolium salts (MTT) were added to each well and after 1-2 h of incubation at 37~ the reaction was stopped with 100/zl/well of an extraction buffer (20% SDS, 50% DMF, 2.5% 1.0 N HC1, 2.5% of 80% acetic acid, pH 7.4). After overnight incubation at 37~ OD were measured at 540 nm using an automated microELISA autoreader. One unit of Ib6 corresponds to half-maximum growth of the hybridoma cells. IL-6 activity detected in supernatants of LPS-stimulated monocytes and in plasma was completely abolished by the addition of 10/zg rabbit polyclonal anti-human Ib6 antibodies (Genzyme Corp., Boston, MA).
Results
Bi.ding of HA.IA a.d ES to FH~.~S. At a concentration
of 200/zg/ml, HA-1A consistently bound slightly more radiolabeled LPS in comparison to controls (Table 1 ). In two instances (E. coli O1 and E. coli O2), substantial quantities of radiolabeled LPS were bound by HA-1A, but these LPS were bound considerably by control polyclonal human and mouse IgM/HSA as well. In contrast, there was little or no difference in the amount of LPS bound by E5 compared to controls (Table 1) . We varied the concentration of mAbs to compare binding with the O-specific IgG antibody and to see if higher concentrations of anti-lipid A mAbs would be more efficient at binding. These results are shown in Fig.  1 . At very high concentrations (1.6 mg/ml), E5 bound up to 30% of the LPS from certain strains, which was slightly higher than the polyclonal IgM control in this series of experiments, whereas HA-1A bound somewhat less. As expected, the O-specific IgG mAb bound homologous LPS efficiently at low concentrations (half-maximal binding at 5-10 ~g/ml).
Neutralization of LPS as Assessed by Liraulus L2/sate. A rep-
resentative experiment assessing the ability of HA-1A and E5 to neutralize LPS in the limulus lysate assay is shown in Fig. 2 
Discussion
These studies demonstrate that anti-lipid A mAbs HA-1A and E5 bind only weakly to LPS from multiple clinically relevant smooth gram-negative bacteria, and are unable to neutralize the biological effects of LPS in several in vitro assays. Our findings do not support the hypothesis that either of these antibodies is able to protect patients with gram-negative sepsis by binding to lipid A and blocking the toxic effects of endotoxin in the bloodstream.
Each of these mAbs have been described to bind to lipid A and LPS as assessed by ELISA (15, 41) , although a more recent abstract suggested that HA-1A binds only slightly to smooth LPS using this technique (42) . Since solid-phase assays using LPS are difficult to interpret because of nonspecific binding to the solid-phase matrix, we used a fluid-phase ILIA to measure antibody-LPS binding. We found that both HA-1A and E5 bound to radiolabeled smooth LPS compared to irrelevant IgM controls, but that it was necessary to use very high concentrations of IgM to see the effect. We were unable to achieve half-maximal binding of any of the bacterial strains tested even with 1.6 mg/ml HA-1A or E5, whereas half-maximal binding of E. coli Ol11:B4 LPS was achieved at 5-10/~g/ml of an IgG mAb six,tic for the O-polysaccharide of this LPS. The RIA that we used was initially described by Farr (34) , and depends upon the precipitation of antigen-antibody complexes in 50% ammonium sulfate while free antigen remains in solution. We were not able to assess binding of either antibody to rough LPS from E. coli J5 because we found that >90% of this LPS is precipitated by 50% ammonium sulfate. Since high concentrations of HA-1A and E5 were needed to precipitate LPS, we cannot exclude the possibility that some or all of the binding that we measured at high antibody concentrations is nonspecific. It has been suggested that anti-core glycolipid antibodies may interact with LPS in a nonspecific manner through hydrophobic interactions (43) . Indeed, we found that some of the control antibody preparations bound appreciable quantities of LPS at high concentrations.
There is no previously published information on the ability of these two anti-lipid A antibodies to neutralize the biological effects of LPS. We investigated the ability of the mAbs to inhibit LPS-induced activation in the limulus lysate assay and proliferation of routine splenocytes. Lipid A plays a major role in each of these assays (44) . In addition, we studied the capacity of the mAbs to prevent LPS-induced monocyte production of IL-1, IL-6, and TNF. I/.-1 and TNF are felt to be important in the pathogenesis of septic shock (45) (46) (47) (48) (49) (50) , and plasma levels of TNF and Ib6 have been reported to correlate with the outcome of patients with sepsis (51) (52) (53) (54) . Neither HA-1A nor E5 was able to neutralize the effects of LPS in any of the assays we used, even when the antibodies were preincubated in excess with LPS from rough bacterial strains.
Our results need to be viewed with some caution. All of the experiments were performed with LPS that had been extracted chemically. It is possible that the mAbs would bind better to bacterial membrane fragments. Recently, data have been presented in abstract form that HA-1A binds to gramnegative bacteria that have been previously treated with antibiotics that are active against the bacterial cell wall (42) . In addition, it is possible that we would have found more binding or some neutralization if we had used even higher concentrations of antibody in our assays. Nevertheless, the concentrations used in the binding assay are greater than physiologic, and the ratio of antibody to LPS in the neutralization assays that we used for the LAL, mitogenic assay, and cytokine assays were 106 , 103 , and 103 by weight. Although molar ratios would have "~90-fold less than this based on estimated LPS and IgM molecular weights of 10,000 and 900,000, these ratios should have been more than adequate to see some evidence of neutralization, especially given that each antibody is pentameric. Because there are many mediators that contribute to the septic syndrome, it is also possible that the weak binding that we detected could affect mediators of sepsis other than the cytokines we measured, and thereby exert a protective effect. Finally, the binding that we detected could lead to protection by mechanisms other than neutralization, such as by increasing the clearance of LPS.
Since E5 and HA-1A may be used clinically on a widespread basis, further work should be done on their mechanism(s) of action. This knowledge could lead to the development of an in vitro test that correlates with protective efficacy and might indicate which patients would most benefit from these expensive agents.
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